These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 20699411)

  • 61. Orally active inhibitors of human leukocyte elastase. I. Disposition of L-683,845 in rats and rhesus monkeys.
    Vincent SH; Painter SK; Krieter PA; Colletti AE; Lyszack E; Rosegay A; Dean D; Luffer-Atlas D; Miller RR; Cioffe C; Chiu SH
    Drug Metab Dispos; 1996 Dec; 24(12):1369-77. PubMed ID: 8971144
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The disposition of [14C]-labelled benazepril HCl in normal adult volunteers after single and repeated oral dose.
    Waldmeier F; Kaiser G; Ackermann R; Faigle JW; Wagner J; Barner A; Lasseter KC
    Xenobiotica; 1991 Feb; 21(2):251-61. PubMed ID: 2058180
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure.
    Zamek-Gliszczynski MJ; Abraham TL; Alberts JJ; Kulanthaivel P; Jackson KA; Chow KH; McCann DJ; Hu H; Anderson S; Furr NA; Barbuch RJ; Cassidy KC
    Drug Metab Dispos; 2013 Apr; 41(4):714-26. PubMed ID: 23305709
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pharmacokinetics, metabolism and excretion of an inhibitor of inducible nitric oxide synthase, L-NIL-TA, in dog.
    Zhang JY; Wang YF; Milton MN; Beconi M; Chang M; Yin D; Breau AP; Paulson SK
    Xenobiotica; 2003 Nov; 33(11):1159-71. PubMed ID: 14660179
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects.
    Slatter JG; Stalker DJ; Feenstra KL; Welshman IR; Bruss JB; Sams JP; Johnson MG; Sanders PE; Hauer MJ; Fagerness PE; Stryd RP; Peng GW; Shobe EM
    Drug Metab Dispos; 2001 Aug; 29(8):1136-45. PubMed ID: 11454733
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects.
    Mangold JB; Gu H; Rodriguez LC; Bonner J; Dickson J; Rordorf C
    Drug Metab Dispos; 2004 May; 32(5):566-71. PubMed ID: 15100180
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Absorption, distribution, metabolism, and excretion (ADME) of ¹⁴C-sonidegib (LDE225) in healthy volunteers.
    Zollinger M; Lozac'h F; Hurh E; Emotte C; Bauly H; Swart P
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):63-75. PubMed ID: 24817600
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Biotransformation of [
    Pusalkar S; Plesescu M; Gupta N; Hanley M; Venkatakrishnan K; Wu JT; Xia C; Zhang X; Chowdhury S
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):803-814. PubMed ID: 30128949
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Regiospecific and stereospecific triangulation of the structures of metabolites formed by sequential metabolism at multiple prochiral centers.
    Greene RJ; Davis JA; Subramanian R; Deane MR; Emery MG; Slatter JG
    Drug Metab Dispos; 2012 May; 40(5):928-42. PubMed ID: 22328582
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects.
    Gerisch M; Hafner FT; Lang D; Radtke M; Diefenbach K; Cleton A; Lettieri J
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):195-206. PubMed ID: 29188322
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Metabolism and disposition of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist, in healthy human subjects.
    Deng Y; Madatian A; Wire MB; Bowen C; Park JW; Williams D; Peng B; Schubert E; Gorycki F; Levy M; Gorycki PD
    Drug Metab Dispos; 2011 Sep; 39(9):1734-46. PubMed ID: 21646437
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Steady-state disposition of the nonpeptidic protease inhibitor tipranavir when coadministered with ritonavir.
    Chen L; Sabo JP; Philip E; Mao Y; Norris SH; MacGregor TR; Wruck JM; Garfinkel S; Castles M; Brinkman A; Valdez H
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2436-44. PubMed ID: 17485497
    [TBL] [Abstract][Full Text] [Related]  

  • 73.
    Ma J; Laskin OL; Roffel AF; Vaes WHJ; Tang B; Kolnaar J; O'Keefe K; Golden L; Kong R
    Drug Metab Dispos; 2023 Oct; ():. PubMed ID: 37852795
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Metabolism, pharmacokinetics, and excretion of the 5-hydroxytryptamine1b receptor antagonist elzasonan in humans.
    Kamel A; Obach RS; Colizza K; Wang W; O'Connell TN; Coelho RV; Kelley RM; Schildknegt K
    Drug Metab Dispos; 2010 Nov; 38(11):1984-99. PubMed ID: 20668248
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Disposition and biotransformation of the antiretroviral drug nevirapine in humans.
    Riska P; Lamson M; MacGregor T; Sabo J; Hattox S; Pav J; Keirns J
    Drug Metab Dispos; 1999 Aug; 27(8):895-901. PubMed ID: 10421616
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration.
    Hoffmann M; Kasserra C; Reyes J; Schafer P; Kosek J; Capone L; Parton A; Kim-Kang H; Surapaneni S; Kumar G
    Cancer Chemother Pharmacol; 2013 Feb; 71(2):489-501. PubMed ID: 23203815
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A phase I, open-label, mass balance study of [(14)C] dacomitinib (PF-00299804) in healthy male volunteers.
    Bello CL; Smith E; Ruiz-Garcia A; Ni G; Alvey C; Loi CM
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):379-85. PubMed ID: 23760812
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans.
    Takahashi RH; Choo EF; Ma S; Wong S; Halladay J; Deng Y; Rooney I; Gates M; Hop CE; Khojasteh SC; Dresser MJ; Musib L
    Drug Metab Dispos; 2016 Jan; 44(1):28-39. PubMed ID: 26451002
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial.
    Mesa RA; Kantarjian H; Tefferi A; Dueck A; Levy R; Vaddi K; Erickson-Viitanen S; Thomas DA; Cortes J; Borthakur G; Pardanani AD; Estrov Z; Verstovsek S
    Cancer; 2011 Nov; 117(21):4869-4877. PubMed ID: 21480207
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Oral absorption, metabolism and excretion of 1-phenoxy-2-propanol in rats.
    Saghir SA; Brzak KA; Bartels MJ
    Xenobiotica; 2003 Oct; 33(10):1059-71. PubMed ID: 14555341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.